A new pill is being called the greatest progress in treating pancreatic cancer in recent decades. She has contracted tumors in most patients, while some of them have lost sight of cancer.
The medicine is called daraxonensib and produced by the American revolution Medicians. The new results were released this week in Barcelona, in the European-American symposium on cancer therapies.

What did the results show?
The study included 61 patients who had just been diagnosed with advanced pancreatic cancer, which was common in other organs.
In 90 percent of them, tumors stopped growing. Over 60 percent of tumors contracted or disappeared. At about 8 percent – approximately one in twelve patients – cancer was no longer seen in CT scanners.
A year after the treatment began, 76.6 percent of the patients were alive. With chemotherapy alone, they usually survive a year of 40 to 45 percent of patients.
Patients attended, on average, a year and a half, and some of them did not return during this time.
What do the doctors say?
Dr. Wungki Park, oncologist at the Sloan Kettering Cancer Center in New York, who introduced the findings, said that this is the closest thing to recovery. He added that he had never seen so many tumors disappear in patients with widespread cancer.
Imagine, within 18 months the disease just disappears from the scanner, Park said.
The head of the British organisation Cancer Research UK, Michelle Mitchell, called this the biggest step forward we’ve seen in decades for pancreatic cancer patients. However, she warned that more studies are needed. Advertisements
How does the drug work?
Daraxonrasib is the reins of the CRAS. It relates to mutations of CRAS genius, which are found in almost all cases of pancreatic cancer and stimulate tumor growth, and turn them off.
For decades, The CRAS was considered a target that cannot be hit with medicine. Similar mutations have dozens of other types of cancer, so it is hoped that the drug will work for them.
Why is it so much news?
Pancreatic cancer is one of the deadliest. Half of those diagnosed die within three months. When cancer spreads to other organs, only about 3 percent of patients survive five years.
In the spring, a third – stage study of patients who had earlier received chemotherapy indicated that daaxonsanrasib doubled survival compared to chemotherapy, from 6.7 to 13.2 months.
What we do not know
How long can the drug control the disease?
A few patients will achieve complete recovery because doctors say that recovery is not yet possible.
When it will eventually be approved and available outside clinical studies.
What it’s gonna cost.
Will that work for other types of cancer?
Source Layer: Insander





